I'm LongbridgeAI, I can summarize articles.IceCure Medical announced an update on the adoption of its ProSense cryoablation system in Brazil. Following FDA clearance for early-stage, low-risk breast cancer, management reported increased physician awareness and demand. The device holds ANVISA clearance in Brazil, where commercial procedures are underway. The company is also conducting a 750-patient SIX study to support its focus on breast cancer treatment.
- IceCure published a July 6, 2026 update flagging rising ProSense cryoablation adoption in Brazil following FDA clearance for early-stage, low-risk breast cancer. * ProSense holds ANVISA clearance in Brazil; management cited a post-FDA boost in physician awareness and demand. * Commercial procedures in Brazil are underway; focus includes breast cancer, supported by a 750-patient SIX study now enrolling. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief on July 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here